+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5230030
  • Report
  • December 2020
  • Region: Global
  • 200 pages
  • The Business Research Company

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca
  • Bristol -Myers Squibb
  • Immunomedics Inc.
  • Nordic Nanovector Inc.
  • Pfizer Inc.
Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global conjugated monoclonal antibodies market.

This report focuses on conjugated monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the conjugated monoclonal antibodies market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the conjugated monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Conjugated Monoclonal Antibodies market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider conjugated monoclonal antibodies market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The conjugated monoclonal antibodies market section of the report gives context. It compares the conjugated monoclonal antibodies market with other segments of the conjugated monoclonal antibodies market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, conjugated monoclonal antibodies indicators comparison.
Scope

Markets Covered:
1) By Drugs: Adcetris; Kadcyla
2) By Technology: Cleavable Linker; Non-cleavable Linker
3) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumour; Others

Companies Mentioned: Pfizer Inc.; F. Hoffmann-LA; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca
  • Bristol -Myers Squibb
  • Immunomedics Inc.
  • Nordic Nanovector Inc.
  • Pfizer Inc.
1. Executive Summary

2. Conjugated Monoclonal Antibodies Market Characteristics

3. Conjugated Monoclonal Antibodies Market Size and Growth
3.1. Global Conjugated Monoclonal Antibodies Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers of the Market
3.1.2. Restraints on the Market
3.2. Global Conjugated Monoclonal Antibodies Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers of the Market
3.2.2. Restraints on the Market

4. Conjugated Monoclonal Antibodies Market Segmentation
4.1. Global Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Adcetris
  • Kadcyla
4.2. Global Conjugated Monoclonal Antibodies Market, Segmentation by Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Cleavable Linker
  • Non-cleavable Linker
4.3. Global Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumour
  • Others
5. Conjugated Monoclonal Antibodies Market Regional and Country Analysis
5.1. Global Conjugated Monoclonal Antibodies Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Conjugated Monoclonal Antibodies Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Conjugated Monoclonal Antibodies Market
6.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview
6.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Conjugated Monoclonal Antibodies Market
7.1. China Conjugated Monoclonal Antibodies Market Overview
7.2. China Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Conjugated Monoclonal Antibodies Market
8.1. India Conjugated Monoclonal Antibodies Market Overview
8.2. India Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Conjugated Monoclonal Antibodies Market
9.1. Japan Conjugated Monoclonal Antibodies Market Overview
9.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Conjugated Monoclonal Antibodies Market
10.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Conjugated Monoclonal Antibodies Market
11.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Conjugated Monoclonal Antibodies Market
12.1. South Korea Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Conjugated Monoclonal Antibodies Market
13.1. Western Europe Conjugated Monoclonal Antibodies Market Overview
13.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Conjugated Monoclonal Antibodies Market
14.1. UK Conjugated Monoclonal Antibodies Market Overview
14.2. UK Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Conjugated Monoclonal Antibodies Market
15.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Conjugated Monoclonal Antibodies Market
16.1. France Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.2. France Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Conjugated Monoclonal Antibodies Market
17.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview
17.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Conjugated Monoclonal Antibodies Market
18.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Conjugated Monoclonal Antibodies Market
19.1. North America Conjugated Monoclonal Antibodies Market Overview
19.2. North America Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Conjugated Monoclonal Antibodies Market
20.1. USA Conjugated Monoclonal Antibodies Market Overview
20.2. USA Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Conjugated Monoclonal Antibodies Market
21.1. South America Conjugated Monoclonal Antibodies Market Overview
21.2. South America Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Conjugated Monoclonal Antibodies Market
22.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Conjugated Monoclonal Antibodies Market
23.1. Middle East Conjugated Monoclonal Antibodies Market Overview
23.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Conjugated Monoclonal Antibodies Market
24.1. Africa Conjugated Monoclonal Antibodies Market Overview
24.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation by Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Conjugated Monoclonal Antibodies Market Competitive Landscape and Company Profiles
25.1. Conjugated Monoclonal Antibodies Market Competitive Landscape
25.2. Conjugated Monoclonal Antibodies Market Company Profiles
25.2.1. Pfizer Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. F. Hoffmann-LA
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bristol -Myers Squibb
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Merck & Co. Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Immunomedics Inc.
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions in the Conjugated Monoclonal Antibodies Market

27. Conjugated Monoclonal Antibodies Market Trends and Strategies

28. Conjugated Monoclonal Antibodies Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca
  • Bristol -Myers Squibb
  • Immunomedics Inc.
  • Nordic Nanovector Inc.
  • Pfizer Inc.
Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc. and Spectrum Pharmaceuticals Inc.

The global conjugated monoclonal antibodies market is expected to decline from $8.35 billion in 2019 to $8.15 billion in 2020 at a compound annual growth rate (CAGR) of -2.36%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $10.41 billion in 2023 at a CAGR of 8.49%.

The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (mAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to the normal cells in other parts of the body.

North America was the largest region in the conjugated monoclonal antibodies market in 2019.

In July 2020, AstraZeneca, a UK-based drug maker, has entered into a partnership with Daiichi Sankyo for an amount of $6 billion. This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC), which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumor cells. Daiichi Sankyo is a Japan-based pharmaceutical company engaged in the development of antibody-drug conjugates.

The conjugated monoclonal antibodies market covered in this report is segmented by drugs into adcetris; kadcyla. It is also segmented by technology into cleavable linker; non-cleavable linker and by application into blood cancer; breast cancer; ovarian cancer; lung cancer; brain tumour; others.

The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the first FDA-approved radioimmunotherapy drug Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas, which was approved in December 2019, costs between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for many patients and healthcare systems of underdeveloped countries, which hinders the growth of the conjugated monoclonal antibodies market.

Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships. For instance, in October 2019, NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd, collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics, to develop and commercialize Ambrx's internally developed site-specific antibody-drug conjugate, ARX305 used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a US-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered into a collaboration to couple Monopar’s MNPR-101, a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage, to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells.

The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs) are a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs from 2000 to 2018 and in 2019, it has approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer, which in turn aids in the growth of the market.
Note: Product cover images may vary from those shown
  • Pfizer Inc.
  • F. Hoffmann-LA
  • Bristol -Myers Squibb
  • Merck & Co. Inc.
  • Immunomedics Inc.
  • Takeda Pharmaceuticals Industries Ltd.
  • Daiichi Sankyo Company Limited
  • Actinium Pharmaceutical
  • Nordic Nanovector Inc.
  • Spectrum Pharmaceuticals Inc
  • AbbVie Inc
  • Roche Ltd
  • Bayer AG
  • AstraZeneca
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll